-
Featured
Maximizing Clinical Utility of Pulmonary Optical Imaging
Massachusetts General Hospital researchers push the limits of pulmonary optical frequency domain imaging for in vivo diagnosis of lung cancer and assessment of asthmatic airways.
-
Smoking History Predicts Efficacy of Immune Checkpoint Inhibitors in Metastatic Non–Small-Cell Lung Cancer
David C. Christiani, MD, MPH, and colleagues suggest smoking history as an independent surrogate for tumor mutation burden when deciding which patients with advanced non–small-cell lung cancer would benefit from immune checkpoint inhibitor therapy, as smoking pack-years complemented PD-L1 tumor proportion score.
-
Paclitaxel-loaded Mesh Reduces Local Recurrence of Lung Cancer in Animal Model
Yolonda L. Colson, MD, PhD, and colleagues have developed a polymer mesh that can be loaded with a chemotherapeutic agent and implanted during resection to prevent local recurrence. Its use significantly improved survival in a mouse model of non–small-cell lung cancer.
-
New AI Tool Predicts Six-Year Lung Cancer Risk From a Single CT Scan
Lecia V. Sequist, MD, MPH, Florian J. Fintelmann, MD, and colleagues have created and validated Sybil, a convolutional neural network that requires only one low-dose CT scan to predict future lung cancer, regardless of whether visible lung nodules are present and possibly independent of the patient's smoking history.
-
Health-related Quality of Life Among Unmarried Patients Diagnosed With Lung Cancer Worse During COVID-19 Than Before
Laura A. Petrillo, MD, Joseph A. Greer, PhD, and colleagues report the COVID-19 pandemic is not further reducing health-related quality of life (HRQOL) or exacerbating depression among patients with advanced lung cancer. Still, HRQOL is worse among unmarried patients, driven by declines in functional well-being.
-
Review: Managing Lung Cancer in Patients With Interstitial Lung Disease
Massachusetts General Hospital researchers recently summarized evidence about the risk of lung cancer in patients with interstitial lung disease (ILD), considerations for diagnosis and treatment of lung cancer in that population, and monitoring for ILD progression during lung cancer treatment.
Lung Cancer Contributors
-
Aaron Hata, MD, PhD
Assistant Physician, Hematology and Oncology, Massachusetts General Hospital, Assistant Professor of Medicine, Harvard Medical School
Recent Article
Study Provides Insight Into Overcoming Acquired Resistance to KRAS-G12C Inhibitors -
Aaron L. Baggish, MD
Director, Cardiovascular Performance Program, Director, Cardiovascular Performance Program Fellowship
Recent Article
How COVID-19 Affects the Heart, Especially in Athletes -
Gary X. Wang, MD, PhD
Diagnostic Radiologist, Department of Radiology, Massachusetts General Hospital
Recent Article
Some Physicians Knowingly Order Guideline-Discordant Lung Cancer Screening -
Melissa J. Suter, PhD
Associate Professor in Medicine, Harvard Medical School, Assistant in Biomedical Engineering, Massachusetts General Hospital
Recent Article
Maximizing Clinical Utility of Pulmonary Optical Imaging -
Michael T. Lu, MD, MPH
Director of Research, Cardiovascular Imaging Division, Co-Director, Cardiovascular Imaging Research Center, Massachusetts General Hospital, Assistant Professor of Radiology, Harvard Medical School
Recent Article
Q&A: AI Predicts 10-Year Risk of Heart Attack and Stroke from X-Ray Images -
Rebecca Suk Heist, MD, MPH
Associate Professor of Medicine at Harvard Medical School, Physician in the Division of Hematology/Oncology, Mass General Cancer Center
Recent Article
Study Provides Insight Into Overcoming Acquired Resistance to KRAS-G12C Inhibitors -
Udo Hoffmann, MD
Director, Cardiac MR PET CT Program, Mass General, Division Chief, Cardiovascular Imaging, Mass General, Professor of Radiology, HMS
Recent Article
Discordance Across High-Sensitivity Troponin Assays Can Affect Management of Suspected ACS